HSF1 and breast cancer: Our data suggest a mechanism-based rationale for the clinical utilization of HSF1 inhibitors for the treatment of lapatinib-resistant ERBB2-positive breast cancer and/or—in combination with lapatinib—to prevent development of lapatinib resistance.